**ABSTRACT**

**Background:** Cardiac resynchronization therapy (CRT) is beneficial in patients who have heart failure with reduced ejection fraction or arrhythmic events. However, most randomized controlled trials (RCTs) showing survival benefits primarily enrolled older white men. This study aims to evaluate CRT efficacy by sex, race, and age in RCTs.

**Methods:** Five electronic databases (CINAHL, Embase, Emcare, Medline, and PubMed) were searched from inception to July 22, 2021 for RCTs with CRT in adult patients. Data were analyzed for clinical outcomes including all-cause or cardiovascular (CV) death, worsening heart failure (HF), and HF hospitalization (HHF) according to sex, race, and age.

Heart failure (HF) with reduced ejection represents a significant global burden, in which cardiac resynchronization therapy (CRT) has shown therapeutic benefit in certain patients. For instance, the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) randomized controlled trial (RCT) found a decrease in HF events and mortality with CRT and implantable cardioverter-defibrillator (ICD) therapy in HF patients with New York Heart Association (NYHA) class II/III symptoms. Other notable RCTs that investigated the effectiveness of CRT include the COMPANION, 

**RÉSUMÉ**

**Contexte :** La thérapie de resynchronisation cardiaque (TRC) est salutaire chez les patients qui souffrent d’insuffisance cardiaque avec fraction d’éjection réduite ou qui subissent des épisodes arythmiques. Toutefois, la plupart des essais contrôlés randomisés (ECR) montrent des bienséances en matière de survie ont été principalement menés chez des hommes blancs âgés. Cette étude vise à évaluer l’efficacité de la TRC en fonction du sexe, de la race et de l’âge des participants aux ECR.

**Méthodologie :** Nous avons effectué des recherches dans cinq bases de données électroniques (CINAHL, Embase, Emcare, Medline et PubMed) en ciblant une période allant de la date de leur création.

Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) randomized controlled trial (RCT) found a decrease in HF events and mortality with CRT and implantable cardioverter-defibrillator (ICD) therapy in HF patients with New York Heart Association (NYHA) class II/III symptoms. Other notable RCTs that investigated the effectiveness of CRT include the MADIT-CRT randomized controlled trial (RCT) found a decrease in HF events and mortality with CRT and implantable cardioverter-defibrillator (ICD) therapy in HF patients with New York Heart Association (NYHA) class II/III symptoms. Other notable RCTs...
Results: Among six RCTs with up to moderate risk of bias, 54% (n = 3,630 of 6,682; mean age 64 years, 22% female, 8% black patients) had CRT device implantation. All-cause death (odds ratio [OR], 0.51; P = 0.053) was reduced in female versus male CRT patients, whereas CV death, HFH, or all-cause death with worsening HF or HFH did not differ significantly. No difference was seen in CRT patients for all-cause death and worsening HF (OR, 1.32; P = 0.46) among white vs black patients or for all-cause death and HFH (OR, 1.19; P = 0.55) among ≥ 65 versus < 65 years.

Conclusions: Whereas all-cause death was lower in female CRT patients, other reported outcomes did not significantly differ by sex, race, or age. Only 6 studies partially reported outcomes. Thus, enhanced reporting and analyses are required to overcome such paucity of data to evaluate the impact of these factors on clinical outcomes in distinct patient cohorts with CRT indication.

Available to indicate the specific benefits of CRT in more diverse demographic cohorts. In fact, the relationship between sex, race, and age and CRT patient outcomes has produced mixed study results. Although some studies have reported that there is no difference in clinical cardiovascular (CV) outcomes and mortality based on race and age, others suggest that CRT produces notable differences between these populations. Specifically, women may have greater reduction in all-cause death and worsening HF after CRT intervention. Black patients may exhibit a similar reduction in cardiac volumes, but increased risk of HF or death, when compared to white patients after CRT intervention. Older participants (≥ 80 years old) may have a higher mortality risk compared with younger patients after CRT intervention. Collectively, there is no consensus among large RCT data to inform CRT indications based on these important sociocultural factors. Therefore, this systematic review sought to investigate the effect of sex (male or female), race (white or nonwhite) and age (< 65 or ≥65 years old) on CV outcomes and mortality in CRT patients.

Methods

Data sources, search strategy and study eligibility

This review was conducted in accordance with the Preferred Reporting Items Systematic Reviews and Meta-Analyses (PRISMA) guidelines and reported in adherence to relevant ethical guidelines. A search was performed from inception to July 12, 2021 of 5 databases: CINAHL (Cumulative Index to Nursing & Allied Health Literature), Embase, Emcare, Medline (Ovid) and PubMed (non-Medline). The search strategy, developed in collaboration with an Information Specialist (M.P.) using the PICOS framework and search terms used are highlighted (Supplemental Table S1). Search terms included variations of CRT, CRT pacemaker, and CRT defibrillator. RCTs and their secondary analyses that had CRT as an intervention with a control or comparison group were included (even if investigating CRT without indication for HF, such as fine QRS). Studies that provided only short-term outcomes (< 12 months), involved human subjects < 18 years of age, reported on nonhuman subjects, and were published in non–English-language text were excluded from analyses. Studies that conducted secondary analyses of data already included in main trial data were also excluded unless they reported on different clinical outcomes of interest.

Data collection, data extraction and statistical analyses

Search results exported to Endnote X9 (Clarivate Analytics, Philadelphia, PA) were imported to Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia), and duplicate studies were removed. Two independent reviewers (B.M. and N.T.) assessed the titles, abstracts, and full-text manuscripts for study eligibility and data extraction. Data were extracted into standardized spreadsheets for first and corresponding author and funding recipient details, trial origin and enrollment sites, patient details, funding...
type (peer-reviewed or industry), the intervention and control group characteristics, and 1-year event rates for CV outcomes and mortality by sex (male or female), race (white or nonwhite), and age (\( \geq 65 \) or \(< 65 \) years). Data on authorship, funding, and trial details were collected from publications or institutional websites with verification on the clinicaltrials.gov Web site as applicable; funding recipient was presumed to be the corresponding author if not explicitly reported. Article conflicts in the reviewing and extraction stages were resolved by consensus with a third reviewer (M.S.).

Thirteen studies were excluded during the data extraction stage for nondichotomized age ranges and where reported data could not be used in the analysis (Supplemental Tables S2 and S3).

We extracted reported relevant CV outcomes and mortality from the studies that met inclusion criteria. These included 1-year all-cause or CV death, HFH, or composite all-cause death, and worsening HF or HFH. No studies reported on 1-year 3-point major adverse CV events defined as composite myocardial infarction, stroke, and CV death.

Figure 1. Study flow diagram. Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) protocol recommendations were used for study inclusion.
Articles eligible for data extraction* | de Waard et al.\textsuperscript{26} | Ruschitzka et al.\textsuperscript{27} | Biton et al.\textsuperscript{24} (2015)
---|---|---|---
**Trial name** | RAFT\textsuperscript{24} | Echo-CRT\textsuperscript{27} | MADIT-CRT\textsuperscript{3}
**Trials sites** | North America, Australia | Europe | North America, Europe
**No. of trial sites** | 34 | 115 | 110
**Age** | NR | > 18 years | > 21 years
**Patient population** | NYHA class II or III HF, QRS duration > 120 msec, and LVEF < 30% | NYHA class II or IV HF, LVEF < 35%, indication for ICD, QRS < 130 msec, LV diastolic diameter > 55 mm, and evidence of LV desynchronization | Ischemic CM (NYHA class I or II) or non-ischemic CM (NYHA class II), sinus rhythm, LVEF < 30%, prolonged QRS > 130 msec, CM, CHF
**Trial subgroup** | CHF | HF | Composite (ACD, HFH)
**Primary outcome(s)** | Change in 6MWT time and MLWHFQ score | QoL, first HFH, CV death, ACD | ACD, HF
**Secondary outcome(s)** | HFF, change in NYHA class, change in NYAH class, QoL, HFH, CV death | ACD, HF | ACD, HF
**Treatment arm** | CRT-D | CRT-D | CRT-ICD
**Control arm** | ICD | ICD | ICD
**No. of patients (treatment vs control)** | 1798 (894 vs 904) | 809 (404 vs 405) | 1820 (1089 vs 731)

---

6MWT, 6-minute walk test; ACD, all-cause death; AF, atrial fibrillation; APAF-CRT, Ablate and Pace in Atrial Fibrillation; AV, atrioventricular; CM, cardiomyopathy; CRT, cardiac resynchronization therapy; CV, cardiovascular; Echo-CRT, Echocardiography Guided Cardiac Resynchronization Therapy; EF, ejection fraction; HF, heart failure; HFH, HF hospitalization; LV, left ventricular; MADIT-CRT, Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy; NYHA, New York Heart Association; MLWHFQ, Minnesota Living With Heart Failure Questionnaire; QoL, quality of life; NR, not reported; RAFT, Resynchronization-Defibrillation for Ambulatory Heart Failure Trial; CRT, randomized controlled trials.

* Inclusion criteria: Study with human adult subjects ≥ 18 years of age; English language publication; RCT study design with CRT in one arm and at least one clinical outcome as the primary outcome must have at least one clinical outcome. Exclusion criteria: Nonhuman studies; paediatric studies; non--English-language publications; non-RCT study design (eg, observational, case study, cohort, review articles). Elanchenny et al.\textsuperscript{15} and Steffel et al.\textsuperscript{28} were not included in this table, as they report secondary analyses from the same trial as Biton et al.\textsuperscript{24} and Ruschitzka et al.\textsuperscript{27}, respectively. However, Steffel et al.\textsuperscript{28} was still included in the meta-analysis for cardiovascular death, as Ruschitzka et al.\textsuperscript{27} did not report this outcome. Extracted data are from the original RCT or secondary analyses as indicated. Brignole et al.\textsuperscript{24} and Ruschitzka et al.\textsuperscript{27} were original trials, whereas Biton et al.\textsuperscript{24} and de Waard et al.\textsuperscript{26} were secondary analyses of original trials. Brignole et al.\textsuperscript{24} was included in the meta-analysis for outcomes where Biton et al.\textsuperscript{24} did not report the events from MADIT-CRT. The secondary outcomes were also not reported by either sex, race, or age, and so could not be pooled. A\textsuperscript{1}significance at \(P < 0.05\). Comparisons are between intervention and control.

Risk of bias and GRADE assessment

Two reviewers (H.S. and B.M.) independently assessed the risk of bias for included studies using the Cochrane risk-of-bias tool for randomized trials (RoB2).\textsuperscript{21} The 2 reviewers also evaluated overall methodologic bias using individual criteria as either low, high, or some concerns across 5 bias domains (Supplemental Figure S1), which included bias caused by (1) randomization process, (2) deviations from intended intervention, (3) missing outcome data, (4) outcome measurement, and (5) selection of the reported results. The RoB visualizing program, RoBVis,\textsuperscript{22} was used to generate the summary plot to visualize the independent domains for risk of bias. Overall quality of the evidence was also assessed independently by 2 reviewers (H.S. and B.M.) with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)\textsuperscript{23} tool. The overall quality of evidence in the included studies was categorized as either very low, low, moderate, or high. RCTs started with high quality of evidence and were rated downward in the presence of study limitations. Studies were assessed a lower GRADE category for limitations such as risk of bias, indirectness of evidence, heterogeneity, imprecision, or publication bias.

Results

The initial literature search resulted in 8,213 records. After duplicate record removal (n = 3,367), 4,846 articles were screened by title and abstract from which 132 studies were assessed for eligibility. Nineteen studies were identified for potential data extraction, of which 6 studies were included (Fig. 1).\textsuperscript{15,24-28} Of those 6 studies, only 4\textsuperscript{24,26-28} were eligible for meta-analyses, whereas the other 2\textsuperscript{15,25} underwent secondary exclusion but have been reported in the results (Table 1). Thirteen of the 19 studies (original trials or secondary analyses) eligible for data extraction were excluded, as they provided insufficient data to calculate event rates in our analyses (Supplemental Tables S2 and S3). Of the 6 included studies, four RCTs were evaluated to have up to moderate overall bias using the RoB2 tool for methodological quality (Supplemental Figure S1). Elanchenny et al.\textsuperscript{15} (2012) and Steffel et al.\textsuperscript{28} were excluded from this analysis, as they reported on different CV outcomes from the same RCTs as Biton et al.\textsuperscript{24} ([MADIT-CRT])\textsuperscript{23} and Ruschitzka et al.\textsuperscript{27} (the Echocardiography Guided Cardiac Resynchronization Therapy [Echo-CRT] in Heart Failure with a Narrow QRS Complex)\textsuperscript{27} publications. Three studies showed some

---

This page contains a table summarizing the inclusion criteria and study characteristics of trials included in a meta-analysis on cardiac resynchronization therapy (CRT). The table lists the trial name, trial sites, number of trial sites, age, and patient population for each trial. It also includes information on the primary and secondary outcomes, treatment arms, and control arms. The table highlights that the meta-analysis included secondary analyses from trials by Biton et al. and Ruschitzka et al., and the primary outcome for cardiovascular death was not reported by Ruschitzka et al. The meta-analysis included 6 studies, with 4 being eligible for data extraction. The included studies were assessed for methodological quality using the RoB2 tool and were rated downward for limitations. The overall quality of evidence in the included studies was assessed using the GRADE tool. The results section discusses the initial literature search, study eligibility, and the meta-analysis approach. The final section notes that certain studies were excluded due to differences in outcomes from the same RCTs as the included studies.
concerns overall, whereas 1 study showed low risk of bias. The RobVis summary plot to visualize the risk of bias domains for the 4 studies is shown (Supplemental Figure S1), wherein bias caused by deviations from the intended intervention was most concerning, as various stakeholders could not be blinded to implant procedure and/or study methodology. Funnel plot analyses highlighting limited publication bias on clinical outcomes are shown for sex (Supplemental Figure S2), but not for race or age because of limited data on clinical outcomes for such analyses. Chi

Figure 2. Cardiovascular outcomes and mortality between treatment arms by sex in CRT RCTs. Shown are Forest Plot analyses for cardiovascular outcomes and mortality by sex for all-cause death or HFH (A), all-cause death (B), HFH (C), and CV death (D). ACD, all-cause death; CRT, cardiac resynchronization therapy; CVD, cardiovascular death; HFH, HF hospitalization; RCTs, randomized controlled trials.

| Study Subgroup | Female CRT arm Events | Total | Male CRT arm Events | Total | Weight | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|----------------|------------------------|-------|---------------------|-------|--------|-------------------------------|-------------------------------|
| 4.1.2 ACD or HFH |                        |       |                     |       |        |                               |                               |
| de Waard 2019   | 5                      | 136   | 45                  | 758   | 22.8%  | 0.62 [0.25, 1.53]             |                               |
| Ruschitzka 2013 | 18                     | 110   | 50                  | 294   | 77.2%  | 0.96 [0.59, 1.57]             |                               |
| Subtotal (95% CI) | 246                    | 1052  | 100.0%              |       |        | 0.87 [0.56, 1.34]             |                               |
| Total events    | 23                     |       | 95                  |       |        |                               |                               |
| Heterogeneity: Tau² = 0.00; Chi² = 0.72, df = 1 (P = 0.40); I² = 0% |
| Test for overall effect: Z = 0.63 (P = 0.53) |

| Study Subgroup | Female CRT arm Events | Total | Male CRT arm Events | Total | Weight | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|----------------|------------------------|-------|---------------------|-------|--------|-------------------------------|-------------------------------|
| 5.1.3 ACD      |                        |       |                     |       |        |                               |                               |
| Bilin 2015     | 3                      | 239   | 11                  | 522   | 27.3%  | 0.60 [0.17, 2.12]             |                               |
| de Waard 2019  | 4                      | 136   | 28                  | 758   | 41.3%  | 0.60 [0.26, 2.23]             |                               |
| Ruschitzka 2013| 3                      | 110   | 23                  | 294   | 31.4%  | 0.35 [0.11, 1.14]             |                               |
| Subtotal (95% CI) | 485                    | 1574  | 100.0%              |       |        | 0.57 [0.29, 1.07]             |                               |
| Total events   | 10                     |       | 62                  |       |        |                               |                               |
| Heterogeneity: Tau² = 0.00; Chi² = 1.08, df = 2 (P = 0.58); I² = 0% |
| Test for overall effect: Z = 1.68 (P = 0.09) |

| Study Subgroup | Female CRT arm Events | Total | Male CRT arm Events | Total | Weight | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|----------------|------------------------|-------|---------------------|-------|--------|-------------------------------|-------------------------------|
| 6.1.4 HFH      |                        |       |                     |       |        |                               |                               |
| de Waard 2019  | 2                      | 136   | 27                  | 758   | 28.7%  | 0.41 [0.10, 1.72]             |                               |
| Ruschitzka 2013| 17                     | 110   | 40                  | 294   | 71.3%  | 1.14 [0.67, 1.92]             |                               |
| Subtotal (95% CI) | 246                    | 1052  | 100.0%              |       |        | 0.85 [0.34, 2.13]             |                               |
| Total events   | 19                     |       | 67                  |       |        |                               |                               |
| Heterogeneity: Tau² = 0.24; Chi² = 1.79, df = 1 (P = 0.18); I² = 44% |
| Test for overall effect: Z = 0.35 (P = 0.73) |

| Study Subgroup | Female CRT arm Events | Total | Male CRT arm Events | Total | Weight | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|----------------|------------------------|-------|---------------------|-------|--------|-------------------------------|-------------------------------|
| 7.1.5 CVD      |                        |       |                     |       |        |                               |                               |
| de Waard 2019  | 3                      | 136   | 19                  | 758   | 49.7%  | 0.88 [0.26, 2.93]             |                               |
| Steffel 2016   | 3                      | 110   | 19                  | 294   | 50.3%  | 0.42 [0.13, 1.40]             |                               |
| Subtotal (95% CI) | 246                    | 1052  | 100.0%              |       |        | 0.61 [0.26, 1.42]             |                               |
| Total events   | 6                      |       | 38                  |       |        |                               |                               |
| Heterogeneity: Tau² = 0.00; Chi² = 0.73, df = 1 (P = 0.39); I² = 0% |
| Test for overall effect: Z = 1.15 (P = 0.25) |
Table 2. Study patient characteristics by sex, race, and age from included CRT RCTs

| Characteristic | CRT arm (n = 3,630) | Comparator arm (n = 3,052) |
|---------------|--------------------|---------------------------|
| Age (y)       | 63.7 ± 4.8         | 63.8 ± 4.7                |
| Median        | 67                 | 66                        |
| Sex (% of n)  |                    |                           |
| Male          | 72.6 ± 8.5         | 71.6 ± 8.5                |
| Female        | 22.4 ± 8.5         | 28.4 ± 8.5                |
| Race (% of n)*|                    |                           |
| White         | 90.4               | 90.7                      |
| Black         | 8.0                | 7.7                       |

* Data on nonwhite patients other than black patients were not reported.

square and I² tests highlight variable heterogeneity, often low to moderate, depending on the reported clinical outcome (Fig. 2). However, the observed low-to-moderate heterogeneity is likely a consequence of the limited studies eligible for meta-analysis. GRADE assessment for quality of the evidence was deemed high for the included studies.

Study patient demographics

Of the 6,682 patients enrolled in the 6 included studies, 3,630 patients (54%) in the treatment arm with an implanted CRT device were compared with 3,052 patients (46%) in the control arm. Baseline patient characteristics were relatively uniform across the studies (Table 2): The CRT and control groups primarily comprised whites (90% vs 91%) and men (73% vs 72%) who both had a mean age of 64 ± 5 years. Importantly, race and age were particularly limited for our analyses, as only Elanchenny15 reported race-based data for white and black patients but not other nonwhite ethnic groups, and only Ruschitzka et al.22 reported data for age ≥ 65 and < 65 years.

Cardiovascular outcomes and mortality by sex, race, and age

Total event numbers across the 6 studies were derived for all relevant clinical outcome measures. Event numbers were observed to be consistently higher in the comparator arm for nearly all outcomes, except for CV death, which were higher in the CRT treatment arm. CV outcomes data were variably reported as ORs by sex (n studies = 4), race (n studies = 1), and age (n studies = 1) as summarized in Tables 3, 4, and 5. Only CV outcomes data by sex were eligible for meta-analysis from 4 studies and has been reported as RRs in Figure 2 for CRT arm comparisons, and in Supplemental Figures S3 and S4 for treatment and control comparisons. Data were reported by outcome to avoid double counting event rates from the same study.

Variable odds were reported for associated risk of CV outcomes and mortality for between-sex comparisons in the CRT arm. Outcomes with data from only 1 study was reported by Brignole et al.25 for HF death, HFH, or HF (OR, 1.30; 95% CI [0.17, 10.05]; P = 0.80) and Biton et al.24 for all-cause death and worsening HF (OR, 0.69; 95% CI [0.36, 1.35]; P = 0.28).

Outcomes eligible to be pooled included all-cause death and HFH (OR, 1.04; 95% CI [0.64, 1.68], P = 0.87; n studies = 2), HFH (OR, 1.23; 95% CI [0.73, 2.09]; P = 0.44; n studies = 2) or CV death (OR, 0.67; 95% CI [0.28, 1.60]; P = 0.36; n studies = 2), all of which were not significant (Table 3). A modest decrease in all-cause death (OR, 0.51; 95% CI [0.26, 1.01]; P = 0.053, n studies = 3) was observed in women compared with their male counterparts (Table 3).

Meta-analysis by male vs female sex for CRT arm comparisons all favored nonsignificantly toward female CRT arms, including all-cause death or HFH (RR, 0.87; 95% CI [0.56, 1.34]; P = 0.53, £2 = 0.72, df = 1, I² = 0%, n subjects = 1,298, n studies = 2), all-cause death (RR, 0.57; 95% CI [0.29, 1.10]; P = 0.09, £2 = 1.08, df = 2, I² = 0%, n subjects = 2,059, n studies = 3), HFH (RR, 0.85, 95% CI [0.34, 2.13]; P = 0.73, £2 = 1.79, df = 1, I² = 44%, n subjects = 1,298, n studies = 2), and CV death (RR, 0.61; 95% CI [0.26, 1.42]; P = 0.25, £2 = 0.73, df = 1, I² = 0%, n subjects = 1,298, n studies = 2) (Fig. 2). Meta-analysis between treatment and control arms for male sex all yielded nonsignificant differences, including all-cause death or HFH (RR, 0.96; 95% CI

Table 3. Clinical outcomes by sex in CRT RCTs

| Clinical Outcome* | Total | Male sex | Female sex | Odds ratio [95% CI] | P value |
|-------------------|-------|----------|------------|---------------------|---------|
| CRT arm           |       |          |            |                     |         |
| HF death, HFH, or HF | 4/50  | 2/28     | 2/22       | 1.30 [0.17, 10.05]  | 0.80    |
| All-cause death and HF | 49/761| 37/522   | 12/239     | 0.69 [0.36, 1.35]  | 0.28    |
| All-cause death or HFH | 118/1298 | 95/1052 | 23/246     | 1.04 [0.64, 1.68]  | 0.87    |
| All-cause death | 72/2059 | 62/1574  | 10/485     | 0.51 [0.26, 1.01]  | 0.053   |
| HFH               | 86/1298 | 67/1052  | 19/246     | 1.23 [0.73, 2.09]  | 0.44    |
| CV death          | 44/1298 | 38/1052  | 6/246      | 0.67 [0.28, 1.60]  | 0.36    |
| Comparator arm    |       |          |            |                     |         |
| HF death, HFH, or HF | 8/52  | 4/29     | 3/23       | 0.94 [0.19, 4.68]  | 0.94    |
| All-cause death and HF | 66/520 | 44/365  | 22/155     | 1.21 [0.79, 2.09]  | 0.50    |
| All-cause death or HFH | 120/1309 | 90/1023 | 30/286     | 1.21 [0.79, 1.88]  | 0.38    |
| All-cause death | 68/1829 | 53/1388  | 15/441     | 0.89 [0.49, 1.59]  | 0.69    |
| HFH               | 92/1309 | 66/1023  | 26/286     | 1.45 [0.90, 2.32]  | 0.12    |
| CV death          | 38/1309 | 30/1023  | 8/286      | 0.95 [0.43, 2.10]  | 0.90    |

* Number of events per total patients in group at 1 year unless otherwise stated.

Brignole et al.25 was the only study that reported HF death, HFH, or HF as a composite and therefore was not eligible for pooled analysis. Biton et al.24 was the only study that reported all-cause death and HF as a composite and therefore was not eligible for pooled analysis.
Table 4. Clinical outcome by race in CRT RCTs

| Clinical outcome* | Total | White race | Black race | Odds ratio [95% CI] | P value |
|-------------------|-------|------------|------------|---------------------|---------|
| HFH               | 67/404| 36/264     | 31/240     | 1.23 [0.70, 2.18]   | 0.47    |
| All-cause death   | 67/404| 23/126     | 44/278     | 1.19 [0.68, 2.07]   | 0.54    |
| HFH               | 58/404| 20/126     | 38/278     | 1.19 [0.66, 2.15]   | 0.55    |

Table 5. Clinical outcomes by age in CRT RCTs

| Clinical outcome* | Total | < 65 y | ≥ 65 y | Odds ratio [95% CI] | P value |
|-------------------|-------|--------|--------|---------------------|---------|
| CRT arm           |       |        |        |                     |         |
| All-cause death   | 23/126| 12/126 | 11/100 | 1.85 [0.84, 4.07]   | 0.13    |
| HFH               | 20/126| 11/126 | 9/100  | 1.19 [0.66, 2.15]   | 0.55    |
| Comparator arm    |       |        |        |                     |         |
| All-cause death   | 23/141| 12/141 | 11/20  | 1.23 [0.70, 2.18]   | 0.47    |
| HFH               | 19/141| 10/141 | 9/20   | 1.05 [0.58, 1.93]   | 0.87    |

* Number of events per total patients in group at 1 year unless otherwise stated. Nonuniform age data were not reported. Only Ruschitzka et al.27 provided age-based clinical outcomes data.

Discussion

This study primarily focused on investigating CV outcomes and mortality based on sex, race, and age after CRT in patients from 6 included RCT studies. No significant sex, race, or age-specific differences in pooled clinical outcomes were observed in patients after CRT in terms of CV death or composite all-cause death with worsening HF or HFH. The strongest association was seen between female sex and a lower risk of all-cause death (OR, 0.51; P = 0.053). Although limited data were reported on clinical outcomes based on race or age, interesting initial observations were made between white vs black patients and patients ≥ 65 years vs < 65 years of age without CRT intervention. Further evaluation is justified for these patient populations as all-cause death with or without worsening HF were 3-fold or 6-fold higher, respectively, in the control patient cohorts of those studies. These outcomes differences were mitigated with CRT intervention.

This study also found that most CRT RCTs are conducted by white male investigators from North America or Europe, who, in turn, represent most first and corresponding authorship...
Sex differences in CV outcomes and mortality post–CRT

We reported no sex-based differences in most CV outcomes and mortality after CRT intervention in men vs women at 1 year. Although we included 4 CRT RCTs reporting on clinical outcomes dichotomized by sex, women were underrepresented in all of these studies given that they accounted for only 21%-28% of enrolled study subjects. However, all-cause death was reduced in women relative to men by half, with a P value approaching significance. Prior CRT studies found that women tend to have more favourable clinical and echocardiographic outcomes compared with men. Specifically, women may have a greater improvement in left ventricular ejection fraction and related survival benefit after CRT. Future research needs to be adequately powered to detect true sex differences for other clinically relevant outcomes after CRT including HFH.

Race and age differences in CV outcomes and mortality post–CRT

Although we also reported no significant race or age-based differences in clinical outcomes at 1 year post–CRT intervention, these were both based on only 1 study each. Limited research has been conducted with regard to race-based clinical outcomes in CRT patients. In a subanalysis of the use of evidence-based heart failure therapies in the outpatient setting, no race-related differences were reported in all-cause death at 2 years post–CRT. Our findings emphasize the need to address the problematic disparities observed in CRT indication for black and other minority patients who have HF with reduced ejection fraction. This finding is particularly important, as only 8% of enrolled subjects were black participants in the one study reporting on race-related clinical outcomes with CRT.

Our results suggest that CRT may be beneficial in older adults ≥65 years of age, with the caveat that these patients may potentially experience higher rates of adverse clinical outcomes, although none were statistically significant. This finding supports prior findings that CRT remains clinically effective enough to warrant indication for implantation in this patient subgroup. However, this finding contrasts with those from other studies that suggest CRT implantation in populations much older than 65 years may not hold the same benefit as in younger cohorts over an individual’s lifespan but still pose significant periprocedural risks. Additional RCTs with race- and age-specific data reporting are required to determine the risk of adverse clinical outcomes vs therapeutic benefits among our ethnically diverse and aging adult population, which are adequately powered to detect such differences after CRT. Recent cardiology trials found modest increases in the inclusion of more diverse patient populations. For example, it was shown that between the years of 1996 and 2015, the mean percentage of women in published cardiology RCTs increased by 0.29% each year, whereas the mean age increased by 0.15 years. Similarly, a review by Gong et al. found that women enrollment in CRT trials increased by 33% between the years of 2011 and 2015. However, certain patient subgroups continue to be underrepresented and/or underreported in most RCTs, particularly those of nonwhite race and female sex.

Clinical implications and future considerations

Underrepresentation and/or underreporting of study data by sex, race, and age persist among large RCTs evaluating the efficacy of CRT on clinical outcomes including CV sequelae and mortality. While we did not observe differences along these sociocultural demographics because of the small number of studies reporting these data, an important first step to understanding the risks vs benefits on clinical outcomes of CRT intervention in diverse patient populations would be to enhance female, nonwhite, and elderly patient enrollment. Systemic changes in study inclusion and reporting may enable investigation of the interactionality of important demographic variables with clinical outcomes in CRT patients. Intersectionality is clinically relevant and may challenge the current RCT data reporting that has focused on few demographic characteristics, namely, male sex and white race, while largely failing to consider broader principles of equity, diversity, and inclusion in CV medicine. It is undeniable that multiple factors including cultural connectedness may interact and summate to influence CV outcomes and mortality, including a lack of sex and race-based similarities between patients and their physicians.

The CRT RCTs reporting on clinical outcomes in this review had mostly white male principal investigators from North America and Europe, who, in turn, led knowledge dissemination through first or corresponding authorship. Previous work indicates that the physician-patient relationship is positively influenced by a shared identity (eg, sex, race), resulting in higher levels of trust, satisfaction, and intention to treatment adherence. As a result, increased research team diversity, patient enrollment in clinical trials through government or industry-led incentives, and the use of patient-centered communication may help overcome existing knowledge gaps on diverse CV disease patient populations.

Limitations

No study is without limitations. In this review, the effect size of CRT on certain sex, race, or age groups must be evaluated with caution owing to the small number of included studies with sufficiently reported outcomes data. We also did not write to the study authors of the 13 excluded studies to see if they still had access to the relevant outcomes data for inclusion into this analysis. These elements precluded a more robust metaregression. Further, our analyses focused on the capturing event numbers at 1 year, which estimates may not always be accurate owing to some variability between studies in follow-up times and the subgroups investigated. Additionally, shorter and longer clinical outcomes were not explored, but may be warranted, alongside adequately powered studies to allow for sex, race, or age-related clinical outcomes, given the impact on resource utilization in CRT patients over their lifespan.
Conclusions
This study identifies considerable knowledge gaps in the reported efficacy of CRT on the basis of sex, race, or age for clinical outcomes and mortality. Although women may benefit from CRT in terms of a lower risk of all-cause death, the fact that most CV and mortality outcomes reported no differences requires targeted evaluation through diverse leadership dedicated toward the enrollment of distinct sex, race, and age cohorts of HF patients with reduced ejection fraction.

Acknowledgements
We thank Dr Katherine Allan for her input toward this manuscript.

Funding Sources
The authors have no funding sources to declare.

Disclosures
No authors have conflicts of interests to disclose.

References
1. Savarese G, Lund LH. Global public health burden of heart failure. Cardiac Fail Rev 2017;3:3.
2. Hussein AA, Wilkoff BL. Cardiac implantable electronic device therapy in heart failure. Circ Res 2019;124:1584-97.
3. Moss AJ, Hall WJ, Cannon DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38. https://doi.org/10.1056/NEJMoa0906431.
4. Cleland JGF, Daubert J-C, Erdmann E, et al. The Effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1559-49.
5. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834-43.
6. Bristow MR, Saxton LA, Boecher J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
7. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization therapy in chronic heart failure. N Engl J Med 2002;346:1845-53.
8. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-80.
9. Ziaeian B, Zhang Y, Albert NM, et al. Clinical effectiveness of CRT and ICD therapy in heart failure patients by racial/ethnic classification: insights from the IMPROVE HF registry. J Am Coll Cardiol 2014;64:797-807.
10. Champ-Rigot L, Cornille A-L, Ollitrault P, et al. Predictors of clinical outcomes after cardiac resynchronization therapy in patients ≥ 75 years of age: a retrospective cohort study. BMC Geriatr 2019;19:1-8.
11. Heidenreich PA, Tsai V, Bao H, et al. Does age influence cardiac resynchronization therapy use and outcome? JACC Heart Fail 2015;3:497-504.
12. Montenegro Camanho LE, Benchimol Saad E, Slater C, et al. Clinical outcomes and mortality in old and very old patients undergoing cardiac resynchronization therapy. PloS one 2019;14:e0225612.
13. Cheng Y-J, Zhang J, Li W-J, et al. More favorable response to cardiac resynchronization therapy in women than in men. Circ Arrhythm Electrophysiol 2014;7:807-15.
14. Yin F-H, Fan C-L, Guo Y-Y, et al. The impact of gender difference on clinical and echocardiographic outcomes in patients with heart failure after cardiac resynchronization therapy: a systematic review and meta-analysis. PloS one 2017;12:e0176248.
15. Elanchenny M, Moss AJ, McNitt S, et al. Effectiveness of cardiac resynchronization therapy with defibrillator in at-risk black and white cardiac patients. Ann Noninvasive Electrocardiol 2013;18:140-8.
16. Adelstein EC, Liu J, Jain S, et al. Clinical outcomes in cardiac resynchronization therapy-defibrillator recipients 80 years of age and older. Europace 2016;18:420-7.
17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336-41.
18. EndNote [program]. Philadelphia, PA: Clarivate Analytics, 2013.
19. Covidence systematic review software [program]. Melbourne, Australia. Available at www.Covidence.org: Veritas Health Network. Accessed June 10, 2021.
20. Review Manager (RevMan) [program]. Version 5.3 version. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.
21. Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366.
22. McGuinness LA, RobVis: An R package and web application for visualizing risk-of-bias assessments. 2019. Available at: https://github.com/mcguslin/robvis.
23. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
24. Biton Y, Zareba W, Goldenberg I, et al. Sex differences in long-term outcomes with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block. J Am Heart Assoc 2015;4:e002013.
25. Brignole M, Pokushalov E, Pentimalli F, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018;39:3999-4008.
26. de Waard D, Manlucu J, Gillis AM, et al. Cardiac resynchronization therapy in women: a substudy of the resynchronization-defibrillation for ambulatory heart failure trial. JACC Clin Electrophysiol 2019;5:1036-44.
27. Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013;369:1395-405.
28. Steffel J, Varma N, Robertson M, et al. Effect of gender on outcomes after cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCART trial. Circ Arrhythm Electrophysiol 2016;9:e003924.
29. Moss AJ, Hall WJ, Cannon DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38.
30. Ghani A, Delnoy PPH, Adiyaman A, et al. Predictors and long-term outcome of super-responders to cardiac resynchronization therapy. Clin Cardiol 2017;40(5):292-9.
31. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010;122:585-96.

32. Eapen ZJ, Al-Khatib S, Lopes RD, et al. Are racial/ethnic gaps in the use of cardiac resynchronization therapy narrowing? An analysis of 107,096 patients from the national cardiovascular data registry's ICD registry. J Am Coll Cardiol 2012;60:1577-8.

33. Farmer SA, Kirkpatrick JN, Heidenreich PA, et al. Ethnic and racial disparities in cardiac resynchronization therapy. Heart Rhythm 2009;6:325-31.

34. Heidenreich PA, Tsai V. Is anyone too old for an implantable cardioverter-defibrillator? Circ Cardiovasc Qual Outcomes 2009;2:6-8.

35. Olechowski B, Sands R, Zachariah D, et al. Is cardiac resynchronisation therapy feasible, safe and beneficial in the very elderly? J Geriatr Cardiol 2015;12:497.

36. Bunch TJ. Who will benefit from an implantable cardioverter defibrillator? The science of uncertainty and an opportunity for discovery. Am Heart Assoc. 2019.

37. Mikhaylov EN, Lebedev DS. Cardiac resynchronization in the elderly is beneficial, but could we implant our devices in old patients safer? J Geriatr Cardiol 2016;13:277.

38. Nguyen QD, Peters E, Wassef A, et al. Evolution of age and female representation in the most-cited randomized controlled trials of cardiology of the last 20 years. Circ Cardiovasc Qual Outcomes 2018;11: e004713.

39. Berger JS, Melloni C, Wang TY, et al. Reporting and representation of race/ethnicity in published randomized trials. Am Heart J 2009;158: 742-7.

40. Gong JY, Tan NS, Ali SH, et al. Temporal trends of women enrollment in major cardiovascular randomized clinical trials. Can J Cardiol 2019;35: 653-60.

41. Alegria M, Sud S, Steinberg BE, et al. Reporting of participant race, sex, and socioeconomic status in randomized clinical trials in general medical journals, 2015 vs 2019. JAMA Network Open 2021;4: e2111516-e16.

42. Allana S, Ski CF, Thompson DR, et al. Intersectionality and heart failure: what clinicians and researchers should know and do. Curr Opin Support Pall Care 2021;15:141-6.

43. Bey GS, Jesdale B, Forrester S, et al. Intersectional effects of racial and gender discrimination on cardiovascular health vary among black and white women and men in the CARDIA study. SSM-Popul Health 2019;8:100446.

44. Greenwood BN, Carnahan S, Huang L. Patient-physician gender concordance and increased mortality among female heart attack patients. Proc Natl Acad Sci U S A 2018;115:8569-74.

45. Street RL, O’Malley KJ, Cooper LA, et al. Understanding concordance in patient-physician relationships: personal and ethnic dimensions of shared identity. Ann Fam Med 2008;6:198-205.

46. Tang ASL, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363: 2385-95.

**Supplementary Material**

To access the supplementary material accompanying this article, visit *CJC Open* at [https://www.cjcopen.ca/](https://www.cjcopen.ca/) and at [https://doi.org/10.1016/j.cjco.2021.09.005](https://doi.org/10.1016/j.cjco.2021.09.005).